Xencor, Inc. (NASDAQ:XNCR) CEO Sells $1,186,121.46 in Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat sold 49,278 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $24.07, for a total transaction of $1,186,121.46. Following the completion of the sale, the chief executive officer now directly owns 352,615 shares in the company, valued at $8,487,443.05. This represents a 12.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Xencor Trading Up 1.3 %

NASDAQ XNCR opened at $25.62 on Thursday. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $26.84. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $21.65 and a 200-day moving average of $20.41. The company has a market cap of $1.79 billion, a PE ratio of -8.01 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. The firm had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company’s revenue for the quarter was down 81.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.40) earnings per share. On average, equities research analysts anticipate that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

Analysts Set New Price Targets

XNCR has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their price target on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. BMO Capital Markets restated an “outperform” rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and set a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. Finally, Royal Bank of Canada lifted their price objective on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.75.

Hedge Funds Weigh In On Xencor

A number of institutional investors have recently bought and sold shares of XNCR. Point72 Asset Management L.P. lifted its position in shares of Xencor by 147.3% in the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after buying an additional 1,858,440 shares during the last quarter. Logos Global Management LP lifted its holdings in Xencor by 130.8% during the 2nd quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after purchasing an additional 850,000 shares during the last quarter. RA Capital Management L.P. bought a new position in Xencor during the third quarter worth $11,563,000. RTW Investments LP acquired a new position in shares of Xencor in the third quarter valued at $11,563,000. Finally, Braidwell LP bought a new position in shares of Xencor in the third quarter valued at about $9,380,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.